Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

ABSTRACT:

Aims

Anthracycline-induced cardiotoxicity (ACT) occurs in 57% of treated patients and remains an important limitation of anthracycline-based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified. Therefore, we developed evidence-based clinical practice recommendations for pharmacogenomic testing to further individualize therapy based on ACT risk.

Methods

We followed a standard guideline development process, including a systematic literature search, evidence synthesis and critical appraisal, and the development of clinical practice recommendations with an international expert group.

Results

RARG rs2229774, SLC28A3 rs7853758 and UGT1A6 rs17863783 variants currently have the strongest and the most consistent evi

SUBMITTER: Aminkeng F 

PROVIDER: S-EPMC5338111 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature